Targeting Compensatory AKT Activation Overcomes Resistance to AXL Inhibition in Acute Lymphoblastic Leukemia.
It is demonstrated that compensatory AKT activation limits the efficacy of cabozantinib in ALL and the combination of cabozantinib and capivasertib as a promising therapeutic strategy for refractory ALL is established.